A multicenter, Phase 2, randomized, open label, active-controlled, parallel-group study investigating the safety, tolerability, and efficacy of different dose levels of ACP-001 administered once weekly versus standard daily rhGH replacement therapy in pre-pubertal children with Growth Hormone Deficiency (GHD)
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Lonapegsomatropin (Primary) ; Somatropin
- Indications Somatotropin deficiency
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors Ascendis Pharma
- 04 Apr 2017 Results presented at The 99th Annual Meeting of the Endocrine Society
- 03 Apr 2017 According to an Ascendis Pharma media release, results from this trial presented at ENDO 2017, the annual meeting of the Endocrine Society.
- 16 Feb 2017 Results published in an Ascendis Pharma media release.